• Homepage
  • Corporate News
  • PRICE INQUIRY No. SEMA/49/PR84602/2024 – being conducted as a market assessment study
05 December 2024

PRICE INQUIRY No. SEMA/49/PR84602/2024 – being conducted as a market assessment study

In connection with the implementation of the project titled “Design and development of an innovative solution – a drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and supply of the Semaglutide standard (as a free standard).

Details of the price inquiry can be found in the documents attached below.

Polpharma on its websites and mobile applications (“Website”) uses cookies and other related technologies (“cookies”). Self-management of cookies is possible by changing the settings in your web browser. If you do not agree to the collection of personal data through cookies, you can change the settings in your web browser or leave the Website.

By using the Website without changing the settings in your web browser, you accept Polpharma’s use of cookies. By accepting the settings in your web browser, you agree to profiling based on the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect the lawfulness of the processing that was carried out on the basis of consent before its withdrawal.

More information can be found in the Cookies Policy.